Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.32M
Market Cap
$167.84M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 06, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding108,281,240
10 Day Avg. Volume1,381,013
30 Day Avg. Volume1,318,610
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.20Price Target Upside501.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Antibody PotencyBosakitug possesses superior potency and residence time along with unique TSLP binding characteristics, which may position it as a potential best-in-class anti-TSLP therapeutic monoclonal antibody.
Clinical Trial SuccessACRS announced positive topline data from the Phase 2a open-label trial of ATI-2138 in patients with atopic dermatitis.
Pipeline DevelopmentACRS is developing a pair of recently in-licensed antibody assets, indicating continued pipeline progress and potential future growth.
Bears Say
Lack Of Control GroupThe lack of a placebo control in the open-label Ph2a trial for '045 requires caution, even though investors see the data as promising.
Teze DiscontinuationInvestors view Teze data as proof of concept for TSLP inhibition, lending support for '045 despite Teze's discontinuation in AD.
Trial Design ConcernsCompared to the atopic dermatitis clinical landscape, '2138's treatment effect is competitive, though the study's design and sample size are noted.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $167.84M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 4 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 08, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.032.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 108,281,240 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went up 4.8%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
Aclaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (501.31% Upside)
$9.20 (501.31% Upside)
Hedge Fund Trend
Increased
By 597.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.79%
12-Months-Change
Fundamentals
Return on Equity
-91.03%
Trailing 12-Months
Asset Growth
13.80%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$9.20
▲(501.31%Upside)
Technical Analysis
Ownership Overview
29.08% Insiders
5.90% Mutual Funds
1.50% Other Institutional Investors
52.52% Public Companies and Individual Investors